Bronchitis Treatment Market Size, Share & Analysis Report, 2023-2032
The global bronchitis treatment market size was exhibited at USD 7.19 billion in 2022 and is projected to hit around USD 11.96 billion by 2032, growing at a CAGR of 5.22% during the forecast period 2023 to 2032.
Key Pointers:
Bronchitis Treatment Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 7.57 Billion |
| Market Size by 2032 | USD 11.96 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 5.22% |
| Base year | 2022 |
| Forecast period | 2023 to 2032 |
| Segments covered | By Type, By Treatment, By Drug Class, and By Distribution Channel |
| Regional scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key companies profiled | AstraZeneca, Novartis AG, GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Melinta Therapeutics, Sanofi Aventis, Boehringer Ingelheim International GmbH and others. |
Companies investing in bronchitis treatment market are interested in studying the etiology of bronchitis. Key viruses are Influenza type A and B, while key bacterial agents are Streptococcus, Mycoplasma pneumonia, and Staphylococcus. There are several risk factors when population has high disposition to develop chronic bronchitis, particularly in regions where they are exposed to high environmental pollutants. The prevalence of bronchitis is high the general population. In chronic obstructive pulmonary disease (COPD) patients, the prevalence estimates can be as high as 54%. The high burden has been highlighted as a key driver for the evolution of the bronchitis treatment market.
Other key risk factors comprise tobacco smoking, increasing age, socioeconomic status, and occupational exposure. Both pharmacological and non-pharmacological interventions have gathered considerable attention among players in the bronchitis treatment market.
Among the two types, chronic bronchitis holds the leading share of the global market throughout the forecast period. The rise in the opportunities in this segment is the high morbidity and mortality rate. However, rate of developments in prognosis still seems tepid. Coordinated efforts made by all healthcare teams to improve the outcomes of pharmacological treatment for chronic is a key trend driving prospects in the bronchitis treatment market. Further, clinicians recommend making changes in lifestyle in reducing the morbidity of chronic bronchitis.
On the other hand, acute bronchitis is also garnering attention among drug makers and medical device manufacturers. The segment is expected to keep contributing significant revenues in coming years. In developed countries, given the high incidence, an array of studies have been done to understand the risk factors. These studies shed light on expected avenues in the bronchitis treatment market.
Over the years, nonpharmacological interventions have risen in popularity. The various drugs classes are antibiotics, bronchodilators, mucolytics, and, anti-inflammatory drugs. Of these, bronchodilators have been frequently recommended for the treatment of symptomatic COPD.
Advent of novel LAMA/LABA fixed dose combination inhalers has helped in preventing the exacerbations in COPD patients. Thus, long-acting bronchodilators have attracted research targeted toward improving the mechanism. Growing number of clinical trials has helped develop long-acting bronchodilators. The findings of these studies have paved way to guidelines for reducing COPD exacerbations, thus unlocking new prospects for players in the bronchitis treatment market. Introduction of new drug regimens in COPD treatment options has expanded the horizon for stakeholders in the market. This has also led to the approval of novel LAMA/LABA fixed combinations, opening new doors to opportunities for market players.
Bronchitis Treatment Market Segmentation
| By Type | By Treatment | By Drug Class | By Distribution Channel |
|
|
|
|
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Bronchitis Treatment Market
5.1. COVID-19 Landscape: Bronchitis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Bronchitis Treatment Market, By Type
8.1. Bronchitis Treatment Market, by Type, 2023-2032
8.1.1. Acute Bronchitis
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Chronic Bronchitis
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Bronchitis Treatment Market, By Treatment
9.1. Bronchitis Treatment Market, by Treatment, 2023-2032
9.1.1. Drugs
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Oxygen Therapy
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Bronchitis Treatment Market, By Drug Class
10.1. Bronchitis Treatment Market, by Drug Class, 2023-2032
10.1.1. Anti-Inflammatory Drugs
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Antibiotics
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Bronchodilators
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Mucolytic
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Bronchitis Treatment Market, By Distribution Channel
11.1. Bronchitis Treatment Market, by Distribution Channel, 2023-2032
11.1.1. Online Pharmaceutical Store
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Hospital Pharmacies
11.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Bronchitis Treatment Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.1.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.5.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.1.5.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.1.6.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.1.6.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.2.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.5.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.2.5.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.6.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.2.6.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.7.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.2.7.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.2.8.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.2.8.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.3.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.5.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.3.5.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.6.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.3.6.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.7.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.3.7.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.3.8.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.3.8.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.4.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.5.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.4.5.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.6.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.4.6.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.7.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.4.7.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Type (2020-2032)
12.4.8.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.4.8.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.5.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.5.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.5.5.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Type (2020-2032)
12.5.6.2. Market Revenue and Forecast, by Treatment (2020-2032)
12.5.6.3. Market Revenue and Forecast, by Drug Class (2020-2032)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 13. Company Profiles
13.1. AstraZeneca
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Novartis AG
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. GlaxoSmithKline plc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Dr. Reddy's Laboratories Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Melinta Therapeutics
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Sanofi Aventis
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Boehringer Ingelheim International GmbH
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers